According to a research report, Morgan Stanley has updated its risk-return assessment for TRAD CHI MED (00570). Following the company's preliminary 2025 results announcement, and based on expectations of lower sales and gross margin, the firm has reduced its profit forecasts for 2026 to 2030 by 5% to 12%. Consequently, the target price and bearish scenario valuation have been lowered by 7%; the target price has been cut from HK$1.5 to HK$1.4, with an "Underweight" rating maintained.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments